Guerbet S. A. (GBT) - Total Assets
Based on the latest financial reports, Guerbet S. A. (GBT) holds total assets worth €930.02 Million EUR (≈ $1.09 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check GBT cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Guerbet S. A. - Total Assets Trend (2004–2025)
This chart illustrates how Guerbet S. A.'s total assets have evolved over time, based on quarterly financial data. Explore Guerbet S. A. long-term investment allocation to see how much of total assets are deployed in long-term investments.
Guerbet S. A. - Asset Composition Analysis
Current Asset Composition (December 2025)
Guerbet S. A.'s total assets of €930.02 Million consist of 64.6% current assets and 35.4% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 12.4% |
| Accounts Receivable | €173.66 Million | 18.7% |
| Inventory | €296.37 Million | 31.9% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €32.76 Million | 3.5% |
| Goodwill | €28.77 Million | 3.1% |
Asset Composition Trend (2004–2025)
This chart illustrates how Guerbet S. A.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Guerbet S. A. (GBT) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guerbet S. A.'s current assets represent 64.6% of total assets in 2025, an increase from 60.6% in 2004.
- Cash Position: Cash and equivalents constituted 12.4% of total assets in 2025, up from 4.8% in 2004.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, a decrease from 10.0% in 2004.
- Asset Diversification: The largest asset category is inventory at 31.9% of total assets.
Guerbet S. A. Competitors by Total Assets
Key competitors of Guerbet S. A. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Inspire Medical Systems Inc
NYSE:INSP
|
USA | $911.38 Million |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $90.55 Million |
|
Shanghai General Healthy Information and Technology Co. Ltd.
SHG:605186
|
China | CN¥1.59 Billion |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
China | CN¥805.10 Million |
|
Stratec SE
XETRA:SBS
|
Germany | €443.38 Million |
|
Scandinavian Medical Solutions AS
CO:SMSMED
|
Denmark | Dkr205.86 Million |
|
Duearity AB
ST:DEAR
|
Sweden | Skr10.84 Million |
Guerbet S. A. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.49 | 2.32 | 2.34 |
| Quick Ratio | 1.26 | 1.12 | 1.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €359.47 Million | €335.48 Million | €268.34 Million |
Guerbet S. A. - Advanced Valuation Insights
This section examines the relationship between Guerbet S. A.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.50 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | -10.3% |
| Total Assets | €930.02 Million |
| Market Capitalization | $130.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Guerbet S. A.'s assets below their book value (0.14x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Guerbet S. A.'s assets decreased by 10.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Guerbet S. A. (2004–2025)
The table below shows the annual total assets of Guerbet S. A. from 2004 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €930.02 Million ≈ $1.09 Billion |
-10.34% |
| 2024-12-31 | €1.04 Billion ≈ $1.21 Billion |
+1.17% |
| 2023-12-31 | €1.03 Billion ≈ $1.20 Billion |
+9.11% |
| 2022-12-31 | €939.64 Million ≈ $1.10 Billion |
-6.11% |
| 2021-12-31 | €1.00 Billion ≈ $1.17 Billion |
+5.83% |
| 2020-12-31 | €945.71 Million ≈ $1.11 Billion |
-6.26% |
| 2019-12-31 | €1.01 Billion ≈ $1.18 Billion |
-6.66% |
| 2018-12-31 | €1.08 Billion ≈ $1.26 Billion |
+13.34% |
| 2017-12-31 | €953.59 Million ≈ $1.11 Billion |
-7.25% |
| 2016-12-31 | €1.03 Billion ≈ $1.20 Billion |
+13.92% |
| 2015-12-31 | €902.50 Million ≈ $1.06 Billion |
+89.75% |
| 2014-12-31 | €475.63 Million ≈ $556.07 Million |
+3.50% |
| 2013-12-31 | €459.55 Million ≈ $537.26 Million |
-0.31% |
| 2012-12-31 | €460.97 Million ≈ $538.92 Million |
+2.50% |
| 2011-12-31 | €449.72 Million ≈ $525.77 Million |
+6.57% |
| 2010-12-31 | €422.01 Million ≈ $493.37 Million |
+7.02% |
| 2009-12-31 | €394.32 Million ≈ $461.00 Million |
+2.97% |
| 2008-12-31 | €382.96 Million ≈ $447.72 Million |
+7.21% |
| 2007-12-31 | €357.21 Million ≈ $417.62 Million |
+9.40% |
| 2006-12-31 | €326.51 Million ≈ $381.72 Million |
+10.38% |
| 2005-12-31 | €295.81 Million ≈ $345.84 Million |
+15.70% |
| 2004-12-31 | €255.67 Million ≈ $298.91 Million |
-- |
About Guerbet S. A.
Guerbet SA provides a range of contrast media, medical devices, and digital and AI solutions for diagnostic and interventional imaging worldwide. It offers DOTAREM, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced MRI examinations; Elucirem, a macrocyclic gadolinium-based contrast agent for use in contrast-enhanced resonance imaging; UNIK, a diagnostic imaging interconne… Read more